S1P Agonists with Hydrolysis-Resistant Phosphonate Surrogates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel, potent, and selective agonists for S1P receptors, particularly S1P1, due to the complexity of synthesizing sphingosine-1-phosphate analogs with limited solubility, which hinders the development of receptor-type selective ligands and understanding of their physiological implications.
Innovation Solution
Development of sphingosine-1-phosphate analogs with a phosphate moiety and hydrolysis-resistant surrogates like phosphonates and phosphothionates, along with pro-drugs that can be activated by sphingosine kinase, specifically targeting S1P1, S1P4, and S1P5 receptors, offering long duration of action and potential therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If sphingosine-1-phosphate analogs are synthesized to achieve receptor selectivity, then the ability to study physiological implications and develop targeted therapies is improved, but the synthesis complexity increases and solubility is limited
Solution Approach 1:
The sphingosine-1-phosphate molecule is divided into distinct functional segments: a head group containing the phosphate moiety (or surrogate), a hydrocarbon chain, and optional cyclic structures. This segmentation allows independent optimization of each region for solubility and receptor binding, simplifying the overall synthesis while maintaining selectivity.
Solution Approach 2:
The patent systematically varies chemical parameters including the hydrocarbon chain length (C4-C24), degree of unsaturation (0-6 double bonds), cyclic structure presence, and phosphate group modifications. These parameter changes enable the discovery of analogs with optimal solubility and receptor selectivity profiles without requiring complex synthesis pathways.
2Manufacturing precision
If sphingosine-1-phosphate analogs are synthesized to achieve receptor selectivity, then the ability to study physiological implications and develop targeted therapies is improved, but solubility is limited
Solution Approach 1:
Different regions of the sphingosine-1-phosphate analog are assigned different chemical properties to optimize overall performance. The head group contains the phosphate or hydrolysis-resistant surrogate for water solubility, while the hydrocarbon chain provides lipophilic character for membrane interaction. This local differentiation of chemical properties enables both solubility and receptor selectivity.
Solution Approach 2:
The analogs combine multiple chemical moieties with complementary properties: phosphate groups or surrogates for solubility, hydrocarbon chains for membrane permeability, and cyclic structures for receptor binding affinity. This composite structure achieves both adequate solubility and high receptor selectivity that neither component could achieve alone.
3Duration of action of moving object
If hydrolysis-resistant phosphate surrogates are used, then the duration of action is extended, but the molecular complexity increases
Solution Approach 1:
The patent employs hydrolysis-resistant phosphate surrogates such as fluorophosphonates, isopropyl phosphonates, and methyl phosphonates that mimic the transient nature of natural S1P signaling but resist enzymatic degradation. These surrogates provide extended duration of action through simple structural modifications rather than complex molecular architectures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds provide selective agonism for S1P receptors, evoking lymphopenia and altering lymphocyte trafficking, with potential therapeutic benefits in autoimmune diseases, cancer, and allograft survival, while minimizing side effects through tissue and response specificity.
Implementation Method 1
The EDG receptors are G-protein coupled receptors (GPCRs) and on stimulation propagate second messenger signals via activation of heterotrimeric G-protein alpha (Gα) subunits and beta-gamma (Gβγ) dimers. A conformational shift is induced in the G-Protein Coupled Receptor (GPCR) when the ligand binds to that receptor, causing GDP to be replaced by GTP on the α-subunit of the associated G-proteins
Implementation Method 2
Sphingosine-1-phosphate is formed as a metabolite of sphingosine in its reaction with sphingosine kinase
Implementation Method 3
Reversible biodegradation of S1P is believed to proceed via hydrolysis by ectophosphatases such as the S1P phosphohydrolase
Implementation Method 4
S1P is degraded irreversibly by S1P lyase
Data Source
AI summary
The present invention provides sphingosine-1-phosphate analogs that are potent, and selective agonists at one or more S1P receptors, specifically the S1P1 receptor type. The compounds invention include compounds having a phosphate moiety as well as compounds with hydrolysis-resistant phosphate surrogates such as phosphonates, alpha-substituted phosphonates, and phosphothionates.